109 results
Page 3 of 6
6-K
wfhp3z083vrs0
3 Apr 23
Current report (foreign)
1:30pm
424B5
vg24y0yb1or4i0atle5c
3 Apr 23
Prospectus supplement for primary offering
8:49am
6-K
igvs7 wgzayyafqp
30 Mar 23
Current report (foreign)
8:05am
6-K
vtawah5byr jj7ws9v
6 Dec 22
Current report (foreign)
1:38pm
424B5
gu6k7 kte3
6 Dec 22
Prospectus supplement for primary offering
6:04am
6-K
EX-99.1
xupm q0qh
5 Dec 22
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension
7:03am
6-K
2zc i2qdnir9swrlkc1
2 Dec 22
Current report (foreign)
9:00am
424B5
xme6wu
2 Dec 22
Prospectus supplement for primary offering
6:31am
6-K
6wi7g8a5
1 Dec 22
Current report (foreign)
4:01pm
6-K
EX-99.2
pry7x 4k4
29 Nov 22
RedHill Biopharma Announces Q3/22 Results and Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt
8:05am
6-K
EX-99.1
6mq0f2gup
29 Nov 22
RedHill Biopharma Announces Q3/22 Results and Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt
8:05am
6-K
EX-99.1
wc6ur4orwego6
17 Nov 22
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
8:32am
6-K
EX-99.1
pb8g 5h4mgypmw6
14 Nov 22
Current report (foreign)
7:08am
6-K
EX-99.1
nyw6t9swddr
14 Nov 22
RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for About RedHill Biopharma
6:06am
6-K
EX-99.1
ciwzgm7z 3es
7 Nov 22
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
9:46am
6-K
EX-99.2
a4f y2bx1qctx
7 Nov 22
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
9:46am
6-K/A
EX-99.1
regdyta
7 Nov 22
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
9:34am
6-K/A
EX-99.2
gxfcw17z52xi
7 Nov 22
RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates
9:34am
6-K
EX-99.1
vsrml0 yztexmd
19 Oct 22
RedHill’s Oral Broad-Acting Antiviral, Opaganib, Granted
7:04am
6-K
EX-99.1
qodjt
18 Oct 22
RedHill Biopharma Announces Receipt of Nasdaq Notification
7:05am